Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching premature ovarian insufficiency (POI) may encounter umbilical mesenchymal stem cell (MSC) therapy as an emerging treatment approach. In China, this treatment is available through the Boao Lecheng pilot-first access pathway in Hainan and is described as being in the clinical research / translational application phase. This guide explains what the treatment is, where it is available, who may be considered, its estimated cost, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is UC-MSC Therapy for Premature Ovarian Insufficiency?
UC-MSC therapy uses allogeneic mesenchymal stem cells derived from umbilical cord tissue. The treatment involves local intervention in the ovarian region rather than direct hormone replacement.
The stated mechanism involves paracrine effects from cytokines, growth factors, and exosomes, with the intended biological focus on regulating the local immune and inflammatory environment and supporting blood supply and the ovarian microenvironment. The treatment remains in a clinical research / translational application phase, so available outcomes require professional evaluation and should not be interpreted as proof of a guaranteed benefit.
POI Stem Cell Therapy China: Is It Available?
Yes, this UC-MSC treatment is accessible in China through the Boao Lecheng “pilot first” pathway in Hainan. Its regulatory status is identified as a clinical research / translational application pathway, with Approval No. [2025] No.62 from the State Administration of Traditional Chinese Medicine and a 2025 registration date. It is classified as low risk within the stated regulatory framework.
This pathway is specific to the designated pilot environment and should not be interpreted as nationwide approval of UC-MSC therapy for POI. Treatment access also remains subject to individual medical assessment.
Where Is POI Stem Cell Therapy China Offered?
The treatment is offered at Le Cheng Hospital (Ciming Boao International Hospital), First Affiliated Hospital of Hainan Medical University in Hainan's Boao Lecheng area.
Technical support is provided by the Reproductive Medicine Center, Nanjing Drum Tower Hospital. The treatment uses allogeneic umbilical cord-derived MSCs.
Who May Be Eligible for POI Stem Cell Therapy China?
There are no fixed published eligibility criteria for POI stem cell therapy in China. The attending physician determines suitability on a case-by-case basis, considering ovarian reserve evaluation, the underlying cause of POI, overall medical history, and relevant contraindications.
This means that a diagnosis of POI alone does not establish eligibility for POI stem cell therapy in China. A medical assessment and review of the patient's clinical records are required before treatment can be considered.
Final eligibility is determined by the treating medical team after a face-to-face consultation or a comprehensive review of the patient's medical records. The medical team may also determine whether additional diagnostic testing or evaluations are required before making a treatment decision.
How Much Does POI Stem Cell Therapy China Cost?
The estimated cost is ¥126,000 (approximately US$18,750) per pair. The price is described as an official government-approved price with transparent fees. The USD figure is an approximate reference conversion and may change with currency fluctuations.
The quoted treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or international travel. Confirm the final pricing and exactly what is included directly with the hospital before making travel arrangements.
Why International Patients May Consider This Option
For some international patients with POI, access to a treatment pathway that is not broadly available in their home country may be worth discussing with qualified specialists. China's Lecheng pilot-first pathway provides a supervised route for exploring this treatment at a designated hospital.
This does not establish that UC-MSC therapy is superior to established POI management, nor does availability demonstrate a guaranteed clinical outcome. Individual outcomes vary and require professional medical evaluation.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and premature ovarian insufficiency-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Le Cheng Hospital (Ciming Boao International Hospital), First Affiliated Hospital of Hainan Medical University in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering POI Stem Cell Therapy China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is POI stem cell therapy available in China?
Yes. UC-MSC therapy for POI is available through the Boao Lecheng “pilot first” pathway at Le Cheng Hospital in Hainan, subject to medical assessment. This pathway does not mean nationwide approval.
How much does POI stem cell therapy cost in China?
The estimated price is ¥126,000 per pair, approximately US$18,750 using a USD/CNY rate of about 6.72. Confirm the final price and include services directly with the hospital.
Who may qualify for UC-MSC therapy for premature ovarian insufficiency?
There are no fixed published criteria. The attending physician evaluates ovarian reserve, the underlying cause of POI, and contraindications on a case-by-case basis.
Can international patients explore POI stem cell therapy in China?
International patients can explore the treatment pathway, subject to medical review and eligibility assessment. Remote consultation may be possible before travel.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
